In particular, two basket studies, MSK-IMPACT (actively recruiting) and the NCI molecular analysis for therapy choice (NCI-MATCH) trial, in which patients with AKT-mutant tumours were treated with the ATP-competitive AKT inhibitor AZD5363 (capivasertib) have shown encouraging data with response rates of ∼25% [10]. Here, AKT1 is linked to neoplasm.